SEC Form 4 · accession 0001144204-17-001745
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark I Greene
Director
Period of report
Jan 10, 2017
Accepted (ET)
Jan 11, 2017 · 10:59 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 10, 2017 | A | 16,406 | $0.64 | A | 57,244 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Acquired from Issuer in lieu of cash compensation for board services during the fourth quarter of 2016.